颈动脉内膜剥脱术与颈动脉支架置入术后长期死亡率的比较分析
基于血管质量倡议2003至2013年数据,倾向性匹配分析比较颈动脉内膜剥脱术(CEA,n=29,235)与颈动脉支架置入术(CAS,n=4415)后长期死亡率。CEA组5年死亡率14.0%低于CAS组18.3%,匹配后全因死亡HR为0.76(95%CI 0.69-0.85),症状性患者获益更明显(校正HR 0.69)。
要点
- CEA组5年死亡率14.0%,CAS组18.3%。
- 倾向性匹配后CEA较CAS全因死亡HR 0.76(95%CI 0.69-0.85)。
- 症状性患者校正HR 0.69,无症状患者校正HR 0.80。
核心结论
- 在真实世界实践中,CEA患者较CAS患者具有长期生存优势,且该优势不因风险校正而减弱。
- 尽管随机试验未显示长期生存差异,本观察性研究显示CEA存在生存获益。
研究设计与样本
- 回顾性队列研究,纳入血管质量倡议2003至2013年所有接受CEA(n=29,235)或CAS(n=4415)的患者。
- 通过链接注册数据与相应Medicare理赔文件获取长期死亡率信息。
- 采用Kaplan-Meier法评估长期死亡率,Cox回归计算粗、校正及倾向性匹配(匹配对总数n=4261)的死亡风险比。
主要发现
- 未校正Kaplan-Meier估计5年死亡率CEA组为14.0%,CAS组为18.3%。
- CEA较CAS全因死亡粗HR为0.75(95%CI 0.70-0.81),提示CEA患者死亡可能性较CAS患者低25%。
- 校正年龄、性别及合并症后HR为0.75(95%CI 0.69-0.82)。
- 倾向性匹配分析HR为0.76(95%CI 0.69-0.85)。
- 按症状分层后,症状性患者校正HR为0.69(95%CI 0.61-0.79),无症状患者校正HR为0.80(95%CI 0.71-0.90)。
关键数值与推荐
- 未校正5年死亡率:CEA组14.0% vs CAS组18.3%。
- 粗全因死亡HR:CEA vs CAS为0.75(95%CI 0.70-0.81)。
- 校正后全因死亡HR:CEA vs CAS为0.75(95%CI 0.69-0.82)。
- 倾向性匹配后全因死亡HR:CEA vs CAS为0.76(95%CI 0.69-0.85)。
- 症状性患者校正HR 0.69(95%CI 0.61-0.79)vs 无症状患者校正HR 0.80(95%CI 0.71-0.90)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The value of carotid intervention is predicated on long-term survival for patients to derive a stroke prevention benefit. Randomized trials report no significant difference in survival after carotid endarterectomy (CEA) vs carotid artery stenting (CAS), whereas observational studies of "real-world" outcomes note that CEA is associated with a survival advantage. Our objective was to examine long-term mortality after CEA vs CAS using a propensity-matched cohort. METHODS: We studied all patients who underwent CEA or CAS within the Vascular Quality Initiative from 2003 to 2013 (CEA, n = 29,235; CAS, n = 4415). Long-term mortality information was obtained by linking patients in the registry to their respective Medicare claims file. We assessed the long-term rate of mortality for CEA and CAS using Kaplan-Meier estimation. We assessed the crude, adjusted, and propensity-matched (total matched pairs, n = 4261) hazard ratio (HR) of mortality for CEA vs CAS using Cox regression. RESULTS: The unadjusted Kaplan-Meier estimated 5-year mortality was 14.0% for CEA and 18.3% for CAS. The crude HR of all-cause mortality for CEA vs CAS was 0.75 (95% confidence interval [CI], 0.70-0.81), indicating that patients who underwent CEA were 25% less likely to die before those who underwent CAS. This survival advantage persisted after adjustment for age, sex, and comorbidities (adjusted HR, 0.75; 95% CI, 0.69-0.82). This effect was confirmed on a propensity-matched analysis, with an HR of 0.76 (95% CI, 0.69-0.85). Finally, these findings were robust to subanalyses that stratified patients by presenting symptoms and were more pronounced in symptomatic patients (adjusted HR, 0.69; 95% CI, 0.61-0.79) than in asymptomatic patients (adjusted HR, 0.80; 95% CI, 0.71-0.90). CONCLUSIONS: During the last 15 years, patients who underwent CEA in the Vascular Quality Initiative have a long-term survival advantage over those who underwent CAS in real-world practice. Despite no difference in long-term survival in randomized trials, our observational study demonstrated a survival benefit for CEA that did not diminish with risk adjustment.
引用
- Columbo JA, Martinez-Camblor P, MacKenzie TA, et al. A comparative analysis of long-term mortality after carotid endarterectomy and carotid stenting. J Vasc Surg. 2018. PMID: 29914828. doi:10.1016/j.jvs.2018.03.432
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。